×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SPRO – spero therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SPRO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/29
12:31 am
spro
Spero Therapeutics (NASDAQ:SPRO) was upgraded by analysts at Wall Street
Medium
Report
Spero Therapeutics (NASDAQ:SPRO) was upgraded by analysts at Wall Street
11/28
08:05 am
spro
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Neutral
Report
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/28
08:00 am
spro
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/4
04:05 pm
spro
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Medium
Report
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
10/21
02:00 am
spro
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Medium
Report
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
10/15
07:11 am
spro
Spero Therapeutics (NASDAQ:SPRO) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Spero Therapeutics (NASDAQ:SPRO) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/14
08:00 am
spro
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
Low
Report
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
10/10
08:11 pm
spro
Best Momentum Stock to Buy for October 10th [Yahoo! Finance]
Low
Report
Best Momentum Stock to Buy for October 10th [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
08:45 pm
spro
Form 4 Spero Therapeutics, Inc. For: Nov 07 Filed by: Rajavelu Esther
Medium
Report
Form 4 Spero Therapeutics, Inc. For: Nov 07 Filed by: Rajavelu Esther
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/13
Spero Announces $10 Million Registered Direct Offering of Common Stock
22.4%
3/17 Spero Therapeutics Inc (NASDAQ: SPRO) had its price target lowered by analysts at Stifel Nicolaus from $22.00 to $21.00. They now have a "buy" rating on the stock. 21.5%
5/9 Q1/2019 3/31/2019 EPS -0.290 ZacksConsensus -0.760 ActVsEst 0.470 - Beat 11.5%
9/9 Spero Therapeutics Inc (NASDAQ: SPRO) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 11.0%
8/16 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
6/17 Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference 5.8%
6/20 Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis 5.7%
9/10 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.4%
2/3 Form 4 Spero Therapeutics, Inc. For: Feb 03 Filed by: Keutzer Timothy 5.4%
10/16 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 4.9%
3/17 Spero Therapeutics Inc (NASDAQ: SPRO) had its price target lowered by analysts at Stifel Nicolaus from $22.00 to $21.00. They now have a "buy" rating on the stock. 21.5%
5/9 Q1/2019 3/31/2019 EPS -0.290 ZacksConsensus -0.760 ActVsEst 0.470 - Beat 11.5%
9/9 Spero Therapeutics Inc (NASDAQ: SPRO) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 11.0%
8/16 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
6/17 Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference 5.8%
6/20 Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis 5.7%
9/10 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.4%
2/3 Form 4 Spero Therapeutics, Inc. For: Feb 03 Filed by: Keutzer Timothy 5.4%
10/16 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 4.9%
TOP News Decliners
3/19
Form S-8 Spero Therapeutics, Inc.
-26.1%
3/16 Form 10-K Spero Therapeutics, Inc. For: Dec 31 -18.7%
6/27 Spero Therapeutics Inc (NASDAQ: SPRO) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. -13.3%
3/11 Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection -11.9%
2/28 Form 8-K Spero Therapeutics, Inc. For: Feb 28 -7.8%
3/31 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -7.8%
4/30 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.3%
4/15 Spero Therapeutics Inc (NASDAQ: SPRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. -4.4%
9/26 Spero Therapeutics Announces Presentations at IDWeek 2019 -4.1%
2/14 Form SC 13G/A Spero Therapeutics, Inc. Filed by: Aquilo Capital Management, LLC -4.1%
3/16 Form 10-K Spero Therapeutics, Inc. For: Dec 31 -18.7%
6/27 Spero Therapeutics Inc (NASDAQ: SPRO) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. -13.3%
3/11 Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection -11.9%
2/28 Form 8-K Spero Therapeutics, Inc. For: Feb 28 -7.8%
3/31 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -7.8%
4/30 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.3%
4/15 Spero Therapeutics Inc (NASDAQ: SPRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. -4.4%
9/26 Spero Therapeutics Announces Presentations at IDWeek 2019 -4.1%
2/14 Form SC 13G/A Spero Therapeutics, Inc. Filed by: Aquilo Capital Management, LLC -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: